CANCER'S CAUSE, CANCER'S CURE (13 page)

For over thirty years, the two botanicals, Pao pereira and
Rauwolfia vomitoria
, have successfully been used to manage cancer and viral pathologies throughout Europe. They are well-known by doctors and patients on that continent, yet Dr. Beljanski’s products still remain relatively unknown in the United States because of overwhelming monopolistic practices of America’s version of Big Pharma. The pharmaceutical industry has a vested interest in keeping Beljanski’s findings out of mainstream literature on cancer. But doctors in the U.S., like their counterparts in Europe twenty years ago, are starting to increasingly read more about the success of Beljanski’s discoveries and are wanting additional information.

After witnessing the satisfaction of European patients during my visit to France in September 2003 and more recently during May 2011, I vowed to vigorously but strictly voluntarily devote my time and efforts to raising awareness of the American public to the remarkably turbulent history, yet magnificent oncological and virological success, of this pair of herbal breakthroughs. These alkaloid extracts have already saved so many people in Europe from dying of malignant tumors, I have made it my mission to help the American medical consumer become aware of the possibilities they offer. I have never received any financial remuneration from the Beljanski Foundation or from Dr. Mirko Beljanski’s relatives, except when we interviewed together at a restaurant and Sylvie or Monique Beljanski paid the restaurant tab. I use these herbs myself as an anticancer preventive, and I pay for Beljanski’s supplements the same as does any other consumer or health professional.

Understanding the Bolt Molecules

In order to understand how these anticancer “bolt” molecules selectively penetrate the pathological cell and not the normal cell, it is important to know that when a cell is in the process of becoming cancerous, several meaningful changes occur. Such abnormal alterations are significant because they characterize malignancy. These changes are as follows:

a. the membrane’s porosity alters from non-porous in healthy cells to porous in cancer cells.

b. the cytoplasmic pH* and Rh* are reversed. The cytoplasm is the thick liquid that holds all the various elements of a cell, called organelles.

c. the cell nucleus enlarges into an unusual size. Because the cell’s DNA becomes destabilized, large scale, out-of-control replication starts taking place.

A healthy, non-porous cell will
not
be penetrated by the bolt molecules.

A cancerous cell is porous, so it is able to be penetrated by all sorts of molecules, good and bad. That’s why carcinogens in the presence of a destabilized cell are so detrimental and, conversely, when the bolt molecules present themselves at the cellular wall of a cancer cell, the cancer cell will allow it to enter as it allows any other molecule to enter.

But the bolt molecule has a different effect on the DNA of the cell than a carcinogen. The carcinogen, as we saw in chapter 2, disallows the weak hydrogen bonds of the DNA cell to close up after they have replicated themselves (the destabilization effect). The open strand of DNA will replicate over and over again out of control.

In one study,
for example, Beljanski found that the “unwinding of the cancer DNA is perfectly proportional to the increase in DNA synthesis.” As noted in chapter 3, the more DNA unwinds, or unzips, the more DNA replication and reformation (otherwise known as DNA synthesis) occurs. That is why cancer cells replicate far faster than healthy cells—the cancer cells have DNA whose strands are constantly unwound, thus the increase in cell production.

The bolt molecules work together to kill the out-of-control cells, with the highly positive effect of
eliminating multibillions of cancer cells
. As I said at the beginning of this chapter, I believe that cancer can be cured.

There were numerous studies done by Beljanski’s team to show the effectiveness of the bolt molecules. Beljanski showed how each alkaloid attaches exclusively to tumors in both plants and mice. For example, his team was able to obtain photographs which are marvelously illustrative of the fact that healthy brain cells (specifically astrocytes) are
not
penetrated by the alkaloid, while cancerous cells (in this instance, components of a glioblastoma brain tumor) are quickly penetrated. The penetrating alkaloid enters through the membrane surrounding the nucleus of the cancer cell and destroys the entire cell that provides housing for the cancer. This phenomenon is even more visible under ultraviolet light. The cancer-targeting alkaloids share the property of being naturally fluorescent (under UV light, they glow like a fluorescent light bulb) and Beljanski was able to photograph the phenomenon.

In Vitro
Studies Among Cancer Cells and Normally Healthy Cells

There is a certain protocol that scientists employ when studying a substance that will potentially be used for human consumption. It is first tested
in vitro
, meaning cells that are to be studied are isolated in some special tubes, and experiments on such cells are conducted. When the
in vitro
tests show promise, then the researcher turns to study the substance
in vivo
, literally in living things.
In vivo
happens most often in laboratory mice but will occur in other living organisms as well. Once the substance proves to be effective
in vivo
, then the substance moves to human trials, where it is tested on humans afflicted with the disease being studied.

For
in vitro
tests, microbiological researchers most often use healthy and cancerous human cells able to be cultured in laboratories. This makes it possible to conduct numerous very useful experiments in order to understand the factors related to certain items. Such items include, for example, how the tested products work, the correct dosages, their eventual toxicity, and a great deal more. All types of cells are thus available and such a controlled study is largely conducted in laboratories where conditions are most ideal for achieving accurate results.

After Beljanski found that the Pao pereira and
Rauwolfia vomitoria
herbal extracts reduced UV absorption and replication activity in cancer DNA using the Oncotest, he then proceeded to test the two extracts in a fairly extensive series of
in vitro
tests. Over and over the research proved the same thing:
growth inhibition takes place in cancer cells by coming in contact with the two Beljanski-discovered alkaloids while healthy cells remain untouched
.

Numerous
in vivo
experiments showed Beljanski’s team that the two alkaloid extracts did not attach to normal DNA, and more importantly, did not show any signs of toxicity. In a study done late in Beljanski’s life on the Pao pereira extract, and whose results were published posthumously in 2000, the extract, which the microbiologist dubbed “the plant-derived anticancer agent PB-100,” showed inhibited cell growth in sixteen distinct cancer cells anywhere from 83.78 percent in the designated “ZR-75-1” breast cancer cell to 99.64 percent inhibition in the “U251” brain cancer cell.

From colon cancer to liver, kidney, skin, ovary, pancreas, prostate and thyroid cancers, Pao Pereira showed remarkably high
in vitro
kill rates for all these cancer cells—all in the upper 80 percent to the mid 90 percent range. And according to Stephen Coles, different laboratories in the years following that 2000 study have conducted several similar experiments with the Pao extract. These subsequent studies not only confirmed the high percentage of cancer cells dying but in keeping with the selective properties of the botanical, under the same
in vitro
conditions, normal cell lines were not destroyed.

Time and again, the
in vivo
studies clearly showed that human clinical trials are justified.

In Vivo
Studies Among Plants

During the late 1970s and early 1980s—perhaps over a six-year period—a crucial series of mental attitudes developed for the Beljanski research group. The group’s members strongly sensed and discussed that they were onto a piece of anticancer science that was both fundamental and vital for the health and welfare of all humankind. For Mirko and Monique Beljanski as team leaders, it was the restarting of an intellectual adventure, delving deeply into life’s great unknown. In 1978, the Beljanski’s were unceremoniously removed from the Pasteur Institute. While that was a secure situation in terms of finance, the animosity between Beljanski and Monod made it impossible for Beljanski to continue his work at the famed institute. With faith and enthusiasm, the scientist and his wife found a new home. Their first ten years of independence was with an independent research facility at the University of Ch‰tenay-Malabry School of Pharmacy outside of Paris.

Then, they spent another ten years in an independent, private laboratory in St. Prim, a small village south of Lyons that was created by CIRIS. Over the next twenty years, the husband and wife team along with their coworkers became excited with new findings coming to them almost daily. Their enthusiasm became infectious, especially among their five newly hired fellow investigators engaged in studies involving plant cancers.

A woman who had worked next door in the plant oncology laboratory of the Pasteur Institute, the studious researcher Liliane Le Goff, Ph.D., joined in the Beljanski group’s enthusiasm. Although she knew that Jacques Monod opposed Dr. Beljanski’s concepts. Dr. Le Goff found the courage and perseverance to dedicate twenty-six years of her life collaborating with Beljanski. She ended up spending more time in Mirko’s small laboratory than in her own at the Pasteur! Working with Beljanski was a source of intellectual happiness for her.

Furthermore, Dr. Le Goff soon persuaded another researcher from the Jussieu University’s Faculty of Science to participate with the Beljanski group as well. Because of the valuable information she observed being uncovered, Madame Y. Aaron-Da-Cunha, Ph.D., also became attached and devoted to Beljanski and his team. She turned into a team member and worked diligently despite the external pressure that was exerted on her by the Pasteur Institute’s director to end her collaboration. All three researchers, Dr. Le Goff, Dr. Y. Aaron-Da-Cunha, and Dr. Mirko Beljanski, co-authored and published many biochemistry papers relating to plant cancer induction and plant cancer inhibition.

Plant cancers are induced by a soil-derived type of bacteria known as
Agrobacterium tumefaciens (A. tumefaciens)
. Here is what happens: A wound to the stem or the root of a plant incites an influx of plant hormones which destabilize the plant’s DNA.
This wound excites the
A. tumefaciens
bacteria to inject a type of RNA that tends to become oncogenic, in other words, it causes tumors to develop. When the bacteria inject the oncogenic RNA into the plant, a tumor begins to form shortly thereafter.

The research team found, not surprisingly, that both the Pao and
Rauwolfia
bolt chemical extracts are 90 percent successful at inhibiting these botanical tumors, all without negative or toxic effects on the plant, which continues normal, healthy development.

The four main research teammates consisting of the two Beljanskis, Dr. Le Goff, and Dr. Aaron-Da-Cunha also demonstrated the important role of plant hormones in the process of introducing and inhibiting cancer in plants. Plant hormones may neutralize the anticancer effect of the Beljanski extracts, depending on the amount of each product put into play by the investigators, a fact that was proven to be true later in human hormonal tissue as well.

Many experiments were conducted over the years by the Beljanski research team to better understand the mechanisms and diverse interactions that come into action during this process. It was concluded that the
Rauwolfia
extract could be as valuable for healing cancer in horticulture as it is for sustaining the health of mammals and man.

Massive amounts of botanical research were carried forward and, indeed, it would behoove the world of agriculture to continue the research Beljanski began to find natural, non-toxic ways to treat the scourge of cancer in plants.

In Vivo
Anticancer Studies in Mice

When the original members of Beljanski’s team left the Pasteur Institute in 1978 and went to work for ten years at the pharmaceutical university, they were able to obtain live laboratory animals, making it possible to study cancer in experimental specimens. While they received no funding from the university or the CNRS (the National Center for Scientific Research, the organization that funds research at the Pasteur Institute as well as other scientific organizations in France), they obtained a contract with the French army to investigate ways of protecting against radiation poisoning—the results of which you will learn about in the next few chapters. This move to the Malabry School of Pharmacy proved to be important because it became possible to buy hundreds of laboratory-raised mice and conduct many different types of experiments on them involving the transplantation of various types of cancer cell lines.